[(1S,2R)-2-[[6-carbamoyl-5-[(1-methylpyrazol-3-yl)amino]pyridazin-3-yl]amino]cyclohexyl]carbamic acid
C16H22N8O3 — CID 142721477
Data last refreshed: (MolForge compound catalog, from PubChem)
About [(1S,2R)-2-[[6-carbamoyl-5-[(1-methylpyrazol-3-yl)amino]pyridazin-3-yl]amino]cyclohexyl]carbamic acid
[(1S,2R)-2-[[6-carbamoyl-5-[(1-methylpyrazol-3-yl)amino]pyridazin-3-yl]amino]cyclohexyl]carbamic acid (PubChem CID 142721477) has the molecular formula C16H22N8O3 and a molecular weight of 374.41 g/mol. Its IUPAC name is [(1S,2R)-2-[[6-carbamoyl-5-[(1-methylpyrazol-3-yl)amino]pyridazin-3-yl]amino]cyclohexyl]carbamic acid.
Molecular Properties
| Compound Name | [(1S,2R)-2-[[6-carbamoyl-5-[(1-methylpyrazol-3-yl)amino]pyridazin-3-yl]amino]cyclohexyl]carbamic acid |
|---|---|
| PubChem CID | 142721477 |
| Molecular Formula | C16H22N8O3 |
| Molecular Weight | 374.41 g/mol |
| Exact Mass | 374.18 |
| IUPAC Name | [(1S,2R)-2-[[6-carbamoyl-5-[(1-methylpyrazol-3-yl)amino]pyridazin-3-yl]amino]cyclohexyl]carbamic acid |
| SMILES | Cn1ccc(Nc2cc(N[C@@H]3CCCC[C@@H]3NC(=O)O)nnc2C(N)=O)n1 |
| InChI | InChI=1S/C16H22N8O3/c1-24-7-6-12(23-24)19-11-8-13(21-22-14(11)15(17)25)18-9-4-2-3-5-10(9)20-16(26)27/h6-10,20H,2-5H2,1H3,(H2,17,25)(H,26,27)(H2,18,19,21,23)/t9-,10+/m1/s1 |
| InChIKey | CRVVUGDXAIXNFM-ZJUUUORDSA-N |
| XLogP | 1.04 |
| TPSA | 160.08 Ų |
| H-Bond Donors | 5 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 374.41 |
| LogP ≤ 5 | 1.04 |
| H-Bond Donors ≤ 5 | 5 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 142721477 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.